#ClinGen Region Curation Results
#31 Jan,2020
#Genomic Locations are reported on GRCh38 (hg38): GCF_000001405.36
#https://www.ncbi.nlm.nih.gov/projects/dbvar/clingen
#to create link: https://www.ncbi.nlm.nih.gov/projects/dbvar/clingen/clingen_region.cgi?id=key
#ISCA ID	ISCA Region Name	cytoBand	Genomic Location	Haploinsufficiency Score	Haploinsufficiency Description	Haploinsufficiency PMID1	Haploinsufficiency PMID2	Haploinsufficiency PMID3	Triplosensitivity Score	Triplosensitivity Description	Triplosensitivity PMID1	Triplosensitivity PMID2	Triplosensitivity PMID3	Date Last Evaluated	Loss phenotype OMIM ID	Triplosensitive phenotype OMIM ID
ISCA-46300	15q24 recurrent region (C-D) (includes SIN3A)		chr15:75339446-75680568	3	Sufficient evidence for dosage pathogenicity	27399968	22180641		0	No evidence available				2020-01-13	613406	
ISCA-46299	Xp11.22 region (includes HUWE1)	Xp11.22	tbd	0	No evidence available				3	Sufficient evidence for dosage pathogenicity	22840365	20655035	26692240	2018-11-19		
ISCA-46298	13q12.12 recurrent region (includes SACS and SGCG)	13q12.12	chr13:22970443-24307222	30	Gene associated with autosomal recessive phenotype				0	No evidence available	23239789			2019-11-03	270550,253700	
ISCA-46297	16p12.2 recurrent region (includes OTOA) (distal region)	16p12.2	chr16:21558792-21729102	30	Gene associated with autosomal recessive phenotype				40	Dosage sensitivity unlikely				2019-11-03	607039	
ISCA-46296	15q24 recurrent region (A-C)	15q24.1-q24.2	chr15:72671374-75215971	3	Sufficient evidence for dosage pathogenicity	22180641	19921647		1	Little evidence for dosage pathogenicity	19557438	20860070		2020-01-03		
ISCA-46295	15q13.3 recurrent region (D-CHRNA7 to BP5) (includes CHRNA7 and OTUD7A)	15q13.3	chr15:31727418-32153204	3	Sufficient evidence for dosage pathogenicity	19898479	20236110	22775350	40	Dosage sensitivity unlikely	26968334	22420048		2018-05-10		
ISCA-46291	7q11.23 recurrent distal region (includes HIP1, YWHAG)	7q11.23	chr7:75528718-76433859	2	Some evidence for dosage pathogenicity	21109226	16971481		1	Little evidence for dosage pathogenicity	21109226	27867344		2018-12-31		
ISCA-46290	Xp11.22p11.23 recurrent region (includes SHROOM4)	Xp11.22-p11.23	chrX: 48447780-52444264	0	No evidence available				3	Sufficient evidence for dosage pathogenicity	19716111	21418194	25425167	2017-12-14		300801
ISCA-46288	2q21.1 recurrent region (includes ARHGEF4, GPR148)	2q21.1	chr2:130719936-131172120	1	Little evidence for dosage pathogenicity	22543972	24591035	25661985	0	No evidence available	22543972			2019-09-30		
ISCA-46287	2p24.3 MYCN-DDX1 duplication region	2p24.3	chr2:15568553-16045215						2	Some evidence for dosage pathogenicity	27794475	24161495	23401364	2017-08-07		
ISCA-37516	22q11.2 recurrent region (central, B/C-D) (includes CRKL)	22q11.21	chr22:20377696-21111383	2	Some evidence for dosage pathogenicity	25123976	22893440	26278718	1	Little evidence for dosage pathogenicity	22796526	18414210	19490635	2017-09-14		
ISCA-37501	17q23.1q23.2 recurrent region (includes TBX2, TBX4)	17q23.1-q23.2	chr17:60035641-62198448	3	Sufficient evidence for dosage pathogenicity	20206336	22052739		2	Some evidence for dosage pathogenicity	20598276	24592505		2018-11-19	613355	
ISCA-37500	15q25.2 recurrent region (LCR B-C, proximal)	15q25.2	chr15:82534140-84045981	3	Sufficient evidence for dosage pathogenicity	24352913	23166063	17847001	0	No evidence available				2016-10-13	614294	
ISCA-37498	11q13.2q13.4 recurrent region (includes SHANK2, FGFs)	11q13.2-q13.4	chr11:67996175-71525885	2	Some evidence for dosage pathogenicity	21373257	28211979		0	No evidence available				2018-01-26		
ISCA-37496	2q13 recurrent region (includes BCL2L11)	2q13	chr2:110634616-112347165	2	Some evidence for dosage pathogenicity	26227573	26236398	21255006	2	Some evidence for dosage pathogenicity	26227573	24807792	21255006	2018-06-22		
ISCA-37495	2q11.2 recurrent region (includes ARID5A, LMAN2L)	2q11.2	chr2:96073264-97005692	2	Some evidence for dosage pathogenicity	26227573	19443486		1	Little evidence for dosage pathogenicity	26227573	19443486		2018-06-09		
ISCA-37494	Xq28 recurrent region (int22h1/int22h2-flanked) (includes RAB39B)	Xq28	chrX:154890328-155335092	3	Sufficient evidence for dosage pathogenicity	25927380	21984752		3	Sufficient evidence for dosage pathogenicity	25927380	21984752	24357492	2018-08-30		300815
ISCA-37493	1q43q44 terminal region (includes AKT3)	1q43-q44	chr1:243124428-245154985	3	Sufficient evidence for dosage pathogenicity	17603806	21800092	22678713	0	No evidence available	23794269			2016-10-12	612337	
ISCA-37488	22q11.2 recurrent region (distal type II, E-F)	22q11.22-q11.23	chr22:22776924-23306924	2	Some evidence for dosage pathogenicity	23765049			1	Little evidence for dosage pathogenicity	22140377	26640714		2016-08-11		
ISCA-37486	16p11.2 recurrent region (distal, BP2-BP3) (includes SH2B1)	16p11.2	chr16:28811314-29035178	3	Sufficient evidence for dosage pathogenicity	20808231	19966786	23258348	1	Little evidence for dosage pathogenicity	27240531	23258348		2017-03-09	613444	
ISCA-37483	19q13.3 region (PSG gene cluster)	19q13	chr19:42738644-43237158	40	Dosage sensitivity unlikely				40	Dosage sensitivity unlikely				2014-03-13		
ISCA-37481	3 copies: 16p centromere	16p11.1	chr16:34967717-35913137	40	Dosage sensitivity unlikely				40	Dosage sensitivity unlikely				2013-08-01		
ISCA-37480	3 copies: 15q telomere	15q26.3	chr15:101621277-101981189	0	No evidence available				40	Dosage sensitivity unlikely				2013-11-26		
ISCA-37478	15q11q13 recurrent (PWS/AS) region (BP2-BP3, Class 2)	15q11.2-q13.1	chr15:23465365-28134728	3	Sufficient evidence for dosage pathogenicity	7611294	22045295		3	Sufficient evidence for dosage pathogenicity	9106540	18374305	16840569	2013-11-26	176270,105830	608636
ISCA-37477	1 copy: 14q telomere; 3 copies: 14q telomere	14q32.3	tbd	40	Dosage sensitivity unlikely				40	Dosage sensitivity unlikely				2014-07-31		
ISCA-37476	14q11.2 region (TCRA region)	14q11.2	chr14:21642889-22552154	40	Dosage sensitivity unlikely				40	Dosage sensitivity unlikely				2015-04-09		
ISCA-37472	8p23.1 region (DEFB gene cluster)	8p23.1	chr8:7195664-8273167	40	Dosage sensitivity unlikely				40	Dosage sensitivity unlikely				2014-03-12		
ISCA-37471	1 copy: 6p telomere | 3 copies: 6p telomere	6p25	chr6:259528-339802	40	Dosage sensitivity unlikely				40	Dosage sensitivity unlikely				2014-06-20		
ISCA-37470	1 copy: 2q telomere|3 copies: 2q telomere	2q37.3	tbd	40	Dosage sensitivity unlikely				40	Dosage sensitivity unlikely				2014-04-24		
ISCA-37469	1q21.2 region (polymorphic region)	1q21.2	tbd	40	Dosage sensitivity unlikely				40	Dosage sensitivity unlikely				2014-07-31		
ISCA-37468	Xp11.23 region (includes MAOA and MAOB)	Xp11.23	chrX:43654906-43882474	3	Sufficient evidence for dosage pathogenicity	22365943	20485326	23414621	0	No evidence available				2017-10-11		
ISCA-37467	7q36.3 ZRS (SHH cis-regulatory) duplication region (within LMBR1 intron 5)	7q36.3	chr7:156791102-156791874	0	No evidence available				3	Sufficient evidence for dosage pathogenicity	18178630	18417549	19291772	2018-02-14		174500
ISCA-37449	14q32 region associated with UPD(14) phenotypes	14q32	chr14:99928257-101038192	2	Some evidence for dosage pathogenicity	20179077	18454453		0	No evidence available				2012-05-10	608149	
ISCA-37448	15q11.2 recurrent region (BP1-BP2) (includes NIPA1)	15q11.2	chr15:22782170-23040134	2	Some evidence for dosage pathogenicity	24352232	21359847	25217958	40	Dosage sensitivity unlikely				2017-05-25		
ISCA-37447	DLK1-MEG3 Intergenic DMR	14q32.2	chr14:100725054-100828279	1	Little evidence for dosage pathogenicity	20585555			0	No evidence available				2012-05-10	608149	
ISCA-37446	22q11.2 recurrent (DGS/VCFS) region (proximal, A-D) (includes TBX1)	22q11.21	chr22:18924718-21111383	3	Sufficient evidence for dosage pathogenicity	20301696	27189754		3	Sufficient evidence for dosage pathogenicity	20301749	19254783	18414210	2018-08-31	188400	608363
ISCA-37443	3q29 recurrent region (includes DLG1)	3q29	chr3:196029183-197617791	3	Sufficient evidence for dosage pathogenicity				2	Some evidence for dosage pathogenicity	18241066	18471269	24838842	2016-01-21	609425	611936
ISCA-37442	6q24 region (includes PLAGL1)	6q24	chr6:143922155-144095424	1	Little evidence for dosage pathogenicity	16971482			3	Sufficient evidence for dosage pathogenicity	10615957	8842729	10923638	2016-05-24		601410
ISCA-37441	11p11.2 (Potocki-Shaffer syndrome) region (includes ALX4, EXT2)	11p11.2	chr11:43873250-46130899	3	Sufficient evidence for dosage pathogenicity	15852040	16319823	20140962	0	No evidence available				2013-12-12	601224	
ISCA-37440	2p21 region (includes PREPL and SLC3A1)	2p21	chr2:44183133-44362502	30	Gene associated with autosomal recessive phenotype	11524703	16385448	18234729	0	No evidence available				2012-03-21	606407	
ISCA-37439	Xq28 recurrent region (includes GDI1)	Xq28	chrX:154396223-154555683	0	No evidence available				3	Sufficient evidence for dosage pathogenicity	20004760	17546640	18047645	2016-05-26		300815
ISCA-37438	14q11.2 region including CHD8 and SUPT16H	14q11.2	chr14:21358741-21393828	2	Some evidence for dosage pathogenicity	17545556			0	No evidence available				2012-05-09		
ISCA-37436	17p12 recurrent (HNPP/CMT1A) region (includes PMP22)	17p12	chr17:14194598-15519638	3	Sufficient evidence for dosage pathogenicity	20301566			3	Sufficient evidence for dosage pathogenicity	20301384			2016-10-13	162500	118220
ISCA-37434	1p36 terminal region (includes GABRD)	1p36.33-p36.31	tbd	3	Sufficient evidence for dosage pathogenicity	17918734	18245432	22766398	2	Some evidence for dosage pathogenicity				2016-05-31	607872	
ISCA-37433	22q11.2 recurrent (DGS/VCFS) region (proximal, A-B) (includes TBX1)	22q11.21	chr22:18924718-20299685	3	Sufficient evidence for dosage pathogenicity	20301696	27189754	26278718	3	Sufficient evidence for dosage pathogenicity	20301749	19254783	18414210	2018-08-31	188400	608363
ISCA-37432	17q12 recurrent (RCAD syndrome) region (includes HNF1B)	17q12	chr17:36458167-37854616	3	Sufficient evidence for dosage pathogenicity				3	Sufficient evidence for dosage pathogenicity				2015-08-10	614527	614526
ISCA-37431	17q11.2 recurrent region (includes NF1)	17q11.2	chr17:30780079-31937008	3	Sufficient evidence for dosage pathogenicity				3	Sufficient evidence for dosage pathogenicity	22241097	18183042	25205021	2016-05-28	613675	613675
ISCA-37430	17p13.3 (Miller-Dieker syndrome) region (includes YWHAE and PAFAH1B1)	17p13.3	chr17:1344539-2685615	3	Sufficient evidence for dosage pathogenicity	3391613, 1671808,  1879837,  7634541, 19584063, 12621583			3	Sufficient evidence for dosage pathogenicity	19136950	19520700	23813913	2016-11-09	247200	613215
ISCA-37429	4p16.3 terminal (Wolf-Hirshhorn syndrome) region	4p16.3	tbd	3	Sufficient evidence for dosage pathogenicity				2	Some evidence for dosage pathogenicity				2016-08-11	194190	
ISCA-37428	1q21.1 recurrent (TAR syndrome) region (BP2-BP3, proximal) (includes RBM8A)	1q21.1	chr1:145686999-146048495	1	Little evidence for dosage pathogenicity	22317977	25217958		1	Little evidence for dosage pathogenicity	22317977	25217958		2017-05-18	274000	
ISCA-37425	5q35 recurrent (Sotos syndrome) region (includes NSD1)	5q35.2-q35.3	chr5:176301976-177620792	3	Sufficient evidence for dosage pathogenicity				3	Sufficient evidence for dosage pathogenicity	23599694	23913520		2014-04-10	117550	
ISCA-37424	10q22.3q23.2 recurrent region (LCR-3/4-flanked) (includes BMPR1A)	10q22.3-q23.2	chr10:79923087-86979631	3	Sufficient evidence for dosage pathogenicity	20345475	21248748	24550761	1	Little evidence for dosage pathogenicity	21248748	26383923		2016-10-13	612242	
ISCA-37421	1q21.1 recurrent region (BP3-BP4, distal) (includes GJA5)	1q21.1-q21.2	chr1:147105904-147917509	3	Sufficient evidence for dosage pathogenicity				3	Sufficient evidence for dosage pathogenicity	3298277	3817079		2016-04-14	612474	612475
ISCA-37420	17q21.3 recurrent region (includes KANSL1)	17q21.3	chr17:45627800-46087514	3	Sufficient evidence for dosage pathogenicity	18628315	25217958		2	Some evidence for dosage pathogenicity	19502243	24649381	26565673	2017-09-13	610443	
ISCA-37418	17p11.2 recurrent (SMS/PLS) region (includes RAI1)	17p11.2	chr17:16906714-20309889	3	Sufficient evidence for dosage pathogenicity				3	Sufficient evidence for dosage pathogenicity	17357070	20188345		2013-11-21	182290	610883
ISCA-37417	Xp22.31 recurrent region (includes STS)	Xp22.31	chrX:6537771-8156913	3	Sufficient evidence for dosage pathogenicity				40	Dosage sensitivity unlikely				2016-04-07	308100	
ISCA-37415	16p13.11 recurrent region (includes MYH11)	16p13.11	chr16:15417854-16198408	3	Sufficient evidence for dosage pathogenicity	18550696	19843651	24246141	2	Some evidence for dosage pathogenicity	21614007	23637818	24352232	2016-04-14		
ISCA-37411	15q13.3 recurrent region (BP4-BP5) (includes CHRNA7)	15q13	chr15:30900686-32153204	3	Sufficient evidence for dosage pathogenicity	18278044	19289393	19136953	1	Little evidence for dosage pathogenicity	19372089	18805830	26997942	2018-04-27	612001	
ISCA-37409	16p12.2 recurrent region (includes EEF2K, CDR2)	16p12.2	chr16:21937124-22419483	2	Some evidence for dosage pathogenicity	20154674	24163246	23682798	0	No evidence available				2018-03-23		
ISCA-37408	2p15p16.1 region (includes BCL11A)	2p15-p16.1	chr2:58912065-62261736	3	Sufficient evidence for dosage pathogenicity	16963482	18245392	22579565	1	Little evidence for dosage pathogenicity	22726847	26278498		2016-06-08	612513	
ISCA-37406	16p13.3 region (includes CREBBP)	16p13.3	chr16:3725055-3880120	3	Sufficient evidence for dosage pathogenicity				1	Little evidence for dosage pathogenicity				2016-06-09	610543	
ISCA-37405	2q13 recurrent region (includes NPHP1)	2q13	chr2:110104531-110228181	30	Gene associated with autosomal recessive phenotype				40	Dosage sensitivity unlikely				2016-02-25		
ISCA-37404	15q11q13 recurrent (PWS/AS) region (BP1-BP3, Class 1)	15q11.2-q13.1	chr15:22782170-28134728	3	Sufficient evidence for dosage pathogenicity	7611294	22045295		3	Sufficient evidence for dosage pathogenicity	9106540	18374305	16840569	2013-11-26	176270,105830	608636
ISCA-37401	11p13 (WAGR syndrome) region	11p13	chr11:31781961-32489442	3	Sufficient evidence for dosage pathogenicity				1	Little evidence for dosage pathogenicity	23701296			2016-05-24	194072	
ISCA-37400	16p11.2 recurrent region (proximal, BP4-BP5) (includes TBX6)	16p11.2	chr16:29638676-30188531	3	Sufficient evidence for dosage pathogenicity	20301775	18184952	21841781	3	Sufficient evidence for dosage pathogenicity	18184952	21731881	21841781	2017-02-09	611913	614671
ISCA-37397	22q11.2 recurrent region (distal type I, D-E/F)	22q11.21-q11.22	chr22:21562828-23306924	3	Sufficient evidence for dosage pathogenicity	23765049	21671380	18179902	3	Sufficient evidence for dosage pathogenicity	22140377	19193630	18414210	2015-03-12	611867	
ISCA-37396	15q24 recurrent region (A-D) (includes SIN3A)	15q24.1-q24.2	chr15:72671374-75680568	3	Sufficient evidence for dosage pathogenicity	22180641	19557438	19233321	1	Little evidence for dosage pathogenicity				2018-08-31	614294	
ISCA-37394	2q37.3 terminal region (includes HDAC4)	2q37.3	chr2:239032997-241988449	3	Sufficient evidence for dosage pathogenicity	19752160	23188045	25402011	0	No evidence available				2016-06-13	600430	
ISCA-37393	22q11.21 recurrent (Cat eye syndrome) region (includes CECR2)	22q11.1-q11.21	chr22:16912063-18109094	0	No evidence available	16708226			3	Sufficient evidence for dosage pathogenicity	22890013	22495764	11693792	2014-02-27		115470
ISCA-37392	7q11.23 recurrent (Williams-Beuren syndrome) region (includes ELN)	7q11.23	chr7:73330452-74728172	3	Sufficient evidence for dosage pathogenicity	20301427			3	Sufficient evidence for dosage pathogenicity	26610320			2015-08-06	194050	609757
ISCA-37390	5p15 terminal (Cri du chat syndrome) region	5p15.33-p15.2	chr5:37695-11347150	3	Sufficient evidence for dosage pathogenicity	15635506	11238681		2	Some evidence for dosage pathogenicity				2016-06-21	123450	
